NanoViricides, Inc. – AMEX:NNVC
NanoViricides stock price today
NanoViricides stock price monthly change
NanoViricides stock price quarterly change
NanoViricides stock price yearly change
NanoViricides key metrics
Market Cap | 21.80M |
Enterprise value | N/A |
P/E | -1.81 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.71 |
PEG ratio | -0.13 |
EPS | -0.76 |
Revenue | N/A |
EBITDA | -8.20M |
Income | -8.79M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNanoViricides stock price history
NanoViricides stock forecast
NanoViricides financial statements
| Jun 2022 | 0 | -1.77M | |
|---|---|---|---|
| Mar 2023 | 0 | -1.59M | |
| Jun 2023 | 0 | -3.56M | |
| Mar 2024 | 0 | -1.85M |
| 2026 | 3M | -12.90M | -430.17% |
|---|---|---|---|
| 2027 | 7M | -4.41M | -63.11% |
Analysts Price target
Financials & Ratios estimates
| 2022-10-13 | -0.23 | -0.15 |
|---|---|---|
| 2022-11-14 | -0.11529 | -0.14 |
| 2023-02-15 | -0.14062 | -0.15 |
| Dec 2022 | 20334963 | 464.59K | 2.28% |
|---|---|---|---|
| Mar 2023 | 18576799 | 348.74K | 1.88% |
| Jun 2023 | 16899880 | 2.03M | 12.04% |
| Mar 2024 | 11464907 | 813.33K | 7.09% |
| Jun 2022 | -1.39M | -75.36K | -32.70K |
|---|---|---|---|
| Mar 2023 | -1.73M | -59.30K | 0 |
| Jun 2023 | -1.49M | -2.56K | 0 |
| Mar 2024 | -1.94M | -44.63K | 0 |
NanoViricides alternative data
| Aug 2023 | 17 |
|---|---|
| Sep 2023 | 17 |
| Oct 2023 | 17 |
| Nov 2023 | 17 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
NanoViricides other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2014 | 100000 | 0 |
| Jan 2015 | 85784 | 0 |
| Mar 2015 | 761908 | 0 |
| May 2015 | 75000 | 0 |
| Jun 2015 | 100000 | 0 |
| Jul 2015 | 50000 | 0 |
| Aug 2015 | 100000 | 0 |
| Sep 2015 | 50000 | 0 |
| Oct 2015 | 25000 | 0 |
| Nov 2015 | 25000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BONIUK MILTON 10 percent owner | Common Stock, par value $0.001 per share | 5,500,000 | N/A | N/A | ||
Option | BONIUK MILTON 10 percent owner | Common Stock, par value $0.001 per share | 1,746,288 | N/A | N/A | ||
Purchase | BONIUK MILTON 10 percent owner | Common Stock, par value $0.001 per share | 25,000 | N/A | N/A | ||
Purchase | BONIUK MILTON 10 percent owner | Common Stock, par value $0.001 per share | 14,640 | N/A | N/A | ||
Purchase | BONIUK MILTON 10 percent owner | Common Stock, par value $0.001 per share | 5,202 | N/A | N/A | ||
Purchase | BONIUK MILTON 10 percent owner | Common Stock, par value $0.001 per share | 2,958 | N/A | N/A | ||
Purchase | BONIUK MILTON 10 percent owner | Common Stock, par value $0.001 per share | 2,200 | N/A | N/A | ||
Option | SEYMOUR EUGENE other: Resignation (see Remark .. | Common Stock, par value $0.001 per share | 104,384 | N/A | N/A | ||
Option | DIWAN ANIL director, 10 perc.. | Common Stock Options | 285,715 | N/A | N/A | ||
Option | DIWAN ANIL director, 10 perc.. | Common Stock, par value $0.001 per share | 208,771 | N/A | N/A |
| Insider | Compensation |
|---|---|
| Dr. Anil R. Diwan Ph.D. (1959) Executive Chairman, Pres, Chief Executive Officer & Sec. | $400,000 |
Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA (1959) Chief Financial Officer | $129,600 |
-
What's the price of NanoViricides stock today?
One share of NanoViricides stock can currently be purchased for approximately $1.46.
-
When is NanoViricides's next earnings date?
Unfortunately, NanoViricides's (NNVC) next earnings date is currently unknown.
-
Does NanoViricides pay dividends?
No, NanoViricides does not pay dividends.
-
How much money does NanoViricides make?
NanoViricides has a market capitalization of 21.80M. NanoViricides made a loss 8.29M US dollars in net income (profit) last year or -$0.15 on an earnings per share basis.
-
What is NanoViricides's stock symbol?
NanoViricides, Inc. is traded on the AMEX under the ticker symbol "NNVC".
-
What is NanoViricides's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of NanoViricides?
Shares of NanoViricides can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are NanoViricides's key executives?
NanoViricides's management team includes the following people:
- Dr. Anil R. Diwan Ph.D. Executive Chairman, Pres, Chief Executive Officer & Sec.(age: 66, pay: $400,000)
- Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA Chief Financial Officer(age: 66, pay: $129,600)
-
How many employees does NanoViricides have?
As Jul 2024, NanoViricides employs 7 workers.
-
When NanoViricides went public?
NanoViricides, Inc. is publicly traded company for more then 19 years since IPO on 26 Oct 2005.
-
What is NanoViricides's official website?
The official website for NanoViricides is nanoviricides.com.
-
Where are NanoViricides's headquarters?
NanoViricides is headquartered at 1 Controls Drive, Shelton, CT.
-
How can i contact NanoViricides?
NanoViricides's mailing address is 1 Controls Drive, Shelton, CT and company can be reached via phone at +20 3 9376137.
NanoViricides company profile:
NanoViricides, Inc.
nanoviricides.comAMEX
7
Biotechnology
Healthcare
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Shelton, CT 06484
CIK: 0001379006
ISIN: US6300873022
CUSIP: 630087302
